By using high-performance liquid chromatography, the in vitro conversion of pentamidine to the corresponding amidoximes (N-hydroxypentamidine and N,N'-dihydroxypentamidine) was studied in supernatants of rat liver homogenate centrifuged at 9,000 x g. The presence of the two amidoxime peaks in chromatograms was confirmed by liquid secondary ion mass spectrometry and by unequivocal synthesis of the suspected metabolites. The metabolic reactions were found to be catalyzed by the cytochrome P-450 system (mixedfunction oxidases). The formation of the monohydroxylated product was found to have a Km of 0.48 mM and a Vmax of 29.50 pmol/min per mg of protein, while the dihydroxylated metabolite had a Km of 0.73 mM and a Vmax of 4.10 pmol/min per mg of protein. N,N'-Dihydroxypentamidine was found to have highly reduced antiprotozoal activity in vitro relative to that of pentamidine, and neither of the hydroxylated metabolites nor pentamidine was found to be significantly mutagenic by the Ames test. Contrary to previous reports, pentamidine is readily metabolized to at least two hydroxylated products, and this conversion may be relevant to the clinical use of the compound and to future drug design.
Pentamidine [1,5-di(4-amidinophenoxy)pentane] was synthesized in the late 1930s and has been used in the prophylaxis and treatment of African trypanosomiasis and treatment of antimony-resistant leishmaniasis (24, 32) . The compound was found to be effective against Pneumocystis carinii pneumonia as early as 1957 (22) , but it was not used extensively to treat P. carinii pneumonia until the acquired immunodeficiency syndrome epidemic (31) . Currently, pentamidine is one of the drugs of choice for the treatment of acquired immunodeficiency syndrome-related P. carinii pneumonia (24, 31, 32) .
While the pharmacological properties of pentamidine have been studied for decades (23, 24, 26, 36, 37) , the recent development of sensitive high-performance liquid chromatographic (HPLC) and biological assays has permitted detailed studies of the distribution and pharmacokinetics of the compound (1-3, 12, 13, 16, 17, 27) . However, there have been no published attempts to determine the metabolic fate of pentamidine, largely because of the long-held concept that the drug is metabolically inert (18, 24, 32 ). This conclusion is primarily based on experiments by Launoy et al. (25, 26) , who used pentamidine labeled with 14C in either an amidino or an aliphatic position. Recent work by Clement and Zimmermann (5, (9) (10) (11) demonstrating that benzamidine is converted to the corresponding benzamidoxime in supernatants of rat liver homogenate centrifuged at 9,000 x g (9,000 x g supernatants) strongly suggested that pentamidine could undergo a similar metabolic transformation. In this report we describe the isolation and characterization of two N-hydroxylated metabolites of pentamidine from incubations of the drug in 9,000 x g rat liver preparations. Four additional putative metabolites were observed, but they have not yet been characterized. While several investigators have commented on the possibility of pentamidine metabolism (2, 12, 38) , this study constitutes the first identification of any metabolites of the drug. * Corresponding author.
MATERIALS AND METHODS
Compounds. Pentamidine isethionate was obtained from LyphoMed Inc. (Rosemont, Ill.), and the mono-and dioximes of pentamidine and benzamidoxime were synthesized in the laboratories of R. R. Tidwell by the method of Tiemann (35) . The structures of the compounds are shown in Fig. 1 (ii) Incubation conditions. Two sets of incubations were carried out under similar conditions. For the first experiment, 1.0 ml of liver supernatant and 1. Microsomal incubations were performed as described above for the 9,000 x g supernatant incubations, except that the cofactor mixture contained 2 mg of NADPH per ml, 1.9 mg of MgCl2 per ml, 5 mM glucose-6-phosphate, 0.7 mg of NADP per ml, and 0.1 U of glucose-6-phosphate-dehydrogenase per ml.
(iii) Confirmation of enzyme activity. The presence of mixed-function oxidase enzyme activity was confirmed by measuring aniline hydroxylase activity as described by Imai et al. (21) . Briefly, 1.0 ml of 10 mM aniline instead of pentamidine was added to an incubation mixture and was shaken at 37°C for 30 Mass spectrometry. A large-scale incubation was set up by using 500 mg of pentamidine isethionate in 400 ml of phosphate buffer (pH 7.4) containing 50 ml of cofactor solution (50 mg of NADPH, 47.5 mg of MgCl2 in phosphate buffer) and 80 ml of the 9,000 x g liver homogenate supernatant. The incubation was carried out for 6 h at 37°C in a shaking water bath. Half of this sample was stored at -70°C, and the other half was extracted over C-18 solid-phase extraction columns as previously described. A total of 32 ml of column eluate was dried to approximately 500,ul under a gentle air stream. Standards were prepared by dissolving several crystals of each standard oxime in 1.5 ml of 95% CH3CN-10 mM heptanesulfonate-10 mM TMAC-4.2 mM H3P04 in H20.
Mass spectra were obtained by using a tandem hybrid mass spectrometry-mass spectrometry system (VG 70-250 SEQ; VG, Manchester, United Kingdom) operated in the liquid secondary ion mass spectrometry (LSIMS) mode. Samples were introduced via direct probe by using glycerol as the matrix, a Cs ion gun set at 35 kV, and an 8-kV source potential. Argon was used as the collision gas in an Rf-only collision cell, with the collision energy set at 4 to 7 eV (laboratory reference). Data were acquired by using multichannel acquisition and were not centroided. Mutagenicity assay. The mutagenic potential of pentamidine, N-hydroxypentamidine, N,N'-dihydroxypentamidine, benzamidine, benzamidoxime, and a 30-min incubation of 1.25 mg of pentamidine per ml in 9,000 x g liver homogenate supernatant (with cofactors) was measured by the method of Maron and Ames (29) . Various amounts of individual compounds were suspended in 10% dimethyl sulfoxide, and 0.1 ml was added to 0.1 ml of Salmonella typhimurium TA100 (hisG428 rfa &uvrB; grown to 108 cells per ml) and 0.5 ml of phosphate buffer (pH 7.4). Two milliliters of top agar at 45°C (0.55% agar, 0.46% NaCl, 45,uM L-histidine, 45,uM biotin) was added, mixed, and poured onto agar plates [30 ml of 1.5% agar, 2% glucose, 0.6% MgSO4. 7H20, 6% citric acid, 30% K2HPO4, 10 .5% NaHNH4(PO4) . 4H20]. The plates VOL. 34, 1990 were incubated for 48 h at 37°C, and the His' revertants were enumerated. Control plates that lacked any amidine, amidoxime, or 9,000 x g liver homogenate supematant were also incubated.
Antiprotozoal activity of N,N'-dihydroxypentamidine. (i) Antigiardial assay. The assay for the activity of the dioxime in vitro was performed as described by Boreham et (15, 30) . The concentration of drug necessary to inhibit 50% incorporation of the labeled substrate was calculated.
(ii) Antileishmanial assay. The activity of N,N'-dihydroxypentamidine against Leishmania mexicana amazonensis clone WR669C45 was determined as described in Grogl et al. (19) (14) . Sonicated calf thymus DNA was added to either compound at a 1:10 drug to base ratio, and the change in the midpoint of the thermal denaturation curve (ATm) was measured under low ionic conditions. RESULTS Pentamidine incubations. Standard samples of pentamidine, monooxime, and dioxime were analyzed by HPLC to determine the relative retention times of the compounds.
Pentamidine was found to have a retention time of approximately 12.5 min, while those of the mono-and dioximes of pentamidine were found to be approximately 11.9 and 11.6 min, respectively (Fig. 2) . The aniline hydroxylase activity of the liver preparation was 0.54 ± 0.09 nmol converted per Chromatogram of standard pentamidine and the corresponding amidoximes. Separation was performed with a diisopropyl C-8 column (Zorbax RX) with 22.5 to 45% CH3CN-10 mM heptanesulfonate-10 mM TMAC-4.2 mM H3PO4 in H20 graded over 25 min (as described in the text). Pentamidine had a retention time of 12.5 min (peak a), the monooxime had a retention time of 11.9 min (peak b), and the dioxime had a retention time of 11.6 min (peak c).
min per mg of protein, which demonstrates that microsomal enzymes were both present and active.
Control incubations were set up in which pentamidine, cofactor solution, or the 9,000 x g liver homogenate supernatant was excluded from the normal 30-min incubation mixture. When the 9,000 x g liver homogenate supernatant or cofactor was excluded, only very small peaks could be detected in the region of interest, and no peaks were detected when pentamidine was excluded. (Fig. 3) . In the experimental incubations, when 41.7 puM pentamidine was present in the 9,000 x g liver homogenate. supernatant preparation with cofactor solution, peaks which coeluted with the mono-and dioximes could be. detected Fig. 4 . It is of interest to note that while the two oximes were present in the incubations, there were four other peaks that were not present in the control incubations (Fig. 4, peaks c, d , e, and f).
To determine the enzyme(s) in the 9,000 x g supernatant that was responsible for the metabolism of pentamidine, a series of incubations was performed with both 9,000 x g rat liver homogenate supernatants and. microsomes isolated from these supernatants ( FIG. 3 . Chromatograms of control liver homogenate incubations. Thirty-minute incubations were performed at 37°C by using 3.0 ml of phosphate buffer, 1.0 ml of the 9,000 x g liver homogenate supernatant, 1 b-+, A particular peak was detected by HPLC analysis of a particular sample; -, the peak was not detected.
included in the kinetic plots because of problems with drug solubility at-that concentration.
Mass spectrometry. To confirm the results obtained by HPLC, it was necessary to detect the presence of the two oximes of pentamidine by mass spectrometry. Standard mass spectra were obtained by performing LSIMS on the synthesized oxime standards diluted in the same matrix as the experimental sample (C-18 elution buffer). Since the background level from the ion pair agents in the buffer was high, it was necessary to use mass spectrometry-mass spectrometry. The ion corresponding to the known molecular weight of the standard compound was selected for secondary fragmentation (the monooxime had an M+ 1 ion of 357, and the dioxime had an M+ 1 ion of 373). The spectra of the standard compounds are shown in Fig. 6 . The experimental sample was a larger-scale liver incubation that was extracted over C-18 columns and concentrated 64-fold. LSIMS mass spectrometry-mass spectrometry was performed on this sample by again focusing on the monooxime M + 1 ion of 357 and the dioxime M+ Secondary mass spectra of the mono-and diamidoximes of pentamidine from standards and experimental incubations. LSIMS mass spectrometry-mass spectrometry was performed by direct-probe bombardment of the sample with cesium ions to produce molecular ions. The molecular ion corresponding to the compound of interest was then selected for secondary fragmentation by collision with argon gas. These secondary fragments are shown for the ion at 357 from a liver homogenate incubation of pentamidine (A), the ion at 373 from the same liver homogenate incubation (B), standard monooxime (M+ 1 = 357) (C), and standard dioxime (M+ 1 = 373) (D). Incubation and extraction conditions are outlined in the text. Each spectrum is displayed as percent intensity (I) against mass/charge ratio. sample are shown in Fig. 6 with the standard spectra. The number and intensity of fragment peaks matched well, thus confirming the presence of the mono-and dioximes of pentamidine in the 9,000 x g liver homogenate preparation incubations.
Mutagenicity. Several concentrations of pentamidine, N-hydroxypentamidine, N,N'-dihydroxypentamidine, benzamidine, benzamidoxime, or 9,000 x g liver homogenate supernatant incubation of 1.25 mg of pentamidine per ml were analyzed for mutagenicity by the test of Maron and Ames (29) . Induction of His' revertants of S. typhimurium TA100 measured the relative mutagenicity of each of the compounds ( Table 2) . None of the compounds tested appeared to be strongly mutagenic, but the 30-min liver supernatant incubation of pentamidine was more mutagenic than any of the five drugs at all doses higher than 0.1 ,ug per plate. Pentamidine appeared to be toxic to the cells at doses higher than 2.5 ,ug per plate, and N-hydroxypentamidine appeared to be toxic at doses higher than 0.1 ,ug per plate. While neither benzamidine nor benzamidoxime was highly mutagenic, benzamidoxime appeared to be more genotoxic than benzamidine, confirming the results of Clement et al. (7) . It is clear from the data in Table 2 that neither N-hydroxypentamidine nor N,N'-dihydroxypentamidine is more mutagenic than pentamidine.
Antiprotozoal activity. N,N'-Dihydroxypentamidine was tested in vitro for activity against G. lamblia, L. mexicana amazonensis, and two strains of P. falciparum (W2, chloroquine resistant, mefloquine susceptible; D6, chloroquine susceptible, mefloquine resistant). The drug was tested from 1.372 to 1,000 ,uM against G. lamblia, from 0.137 to 100 ,uM A proposed mode of action for the antiprotozoal activity of pentamidine is by its strong DNA-binding property (14) . The ability of the N,N'-dihydroxy metabolite to bind DNA similarly was investigated by determining the effect of the drug on the thermal denaturation curve of sonicated calf thymus DNA. N,N'-dihydroxypentamidine was found to have a ATm of 0.2°C. In comparison, pentamidine was found to have a ATTm of 10.7°C. Therefore, the N-hydroxylation of pentamidine results in a corresponding loss of almost all the DNA-binding ability of the parent compound.
DISCUSSION
The long-held conception that pentamidine is not metabolized (18, 24, 32) Of obvious medical importance are the efficacy and toxicity profiles of any pentamidine metabolites relative to those of the parent compound. The relative mutagenicities of N-hydroxypentamidine, N,N'-dihydroxypentamidine, and pentamidine were determined by using the test of Maron and Ames (29) . Neither pentamidine nor the two pentamidoximes were found to be highly mutagenic. The (6) . In all cases, it was found that the amidoximes were active, but they were less active then pentamidine. However, we determined that N,N'-dihydroxypentamidine displays highly reduced antiprotozoal activity in vitro when compared with that of pentamidine. In fact, the activity of the diamidoxime in vitro against all the organisms tested was so low that the concentration necessary to inhibit 50% incorporation of the labeled substrate could not be calculated for the compound. It is likely that the difference seen between in vivo and in vitro activity is due to the occurrence of the reverse reaction (amidoxime to amidine) in vivo. This reaction has been demonstrated previously (8, 20) and could convert enough of the pentamidoxime to pentamidine to produce the low levels of activity seen in vivo. Additionally, N,N'-dihydroxypentamidine was found to have no significant DNA-binding ability (,ATm, 0.2°C). Since the strong DNA binding of pentamidine (ATm, 10.7°C) is a postulated mode of action for the drug, this result may explain the relative inactivity of the amidoxime. The N-hydroxylation pathway of pentamidine appears to cause a significant loss of antiprotozoal activity and, therefore, may be of consequence in the treatment of P. carinii pneumonia. The full impact of metabolism on the biological activity of pentamidine will not be known until all metabolites have been identified, characterized, and tested for antiprotozoal activity.
The observation that pentamidine is readily metabolized requires reexamination of current pentamidine detection methods. Our previous HPLC method for detecting pentamidine is inadequate for detecting any of the putative metabolites. A comparatively less acidic reversed-phase column is effective in separating both the parent diamidine and its corresponding amidoximes (33) . HPLC methods for the detection of pentamidine used by other investigators operate on principles similar to those of our original procedure (16, 27) and should be subject to the same problems. The chemical detection method used by several investigators (24, 36, 37) is based on the conversion of pentamidine to a fluorogenic compound with glyoxal and benzaldehyde, and the bioassay used by Bernard et al. (3) is based on the ability of pentamidine to inhibit Candida tropicalis ATCC 28707 growth. While it is likely that the pentamidoximes would not react in either of these assays, it is not possible to predict the reactivities of the putative metabolites. Therefore, it is difficult to assess the effectiveness of these two assays in the pharmacokinetic study of pentamidine.
With respect to future antimicrobial drug development, it will be necessary to design analogs of pentamidine with consideration of the metabolic fate of the drug. Several novel pentamidine analogs with increased anti-P. carinii activity and lowered toxicity have been synthesized in our laboratories (34) , and the relationship between these properties and metabolism must be thoroughly investigated. Only when the metabolic fate of pentamidine is fully determined will it be possible to fully characterize the pharmacology of the compound and begin a logical search for safer, more effective anti-P. carinii agents.
